Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

NCT02195869 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT02195869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02195869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 1/2
Overall status
Completed
Start date
July 14, 2014
Completion date
September 15, 2017
Enrollment
45 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease